QIAGEN and CENTOGENE to Collaborate in Bioinformatics for Genetic Diseases
October 09 2017 - 4:05PM
PR Newswire (US)
HILDEN and ROSTOCK, Germany and GERMANTOWN, Maryland, October 9, 2017 /PRNewswire/ --
QIAGEN (NASDAQ: QGEN; Frankfurt Prime
Standard: QIA) and CENTOGENE AG today announced a collaboration and
co-marketing agreement to provide customers more complete Sample to
Insight research and clinical testing solutions in rare genetic
diseases. CENTOGENE is a leading rare disease company providing
insights into the complex interaction between genetics,
biochemistry and clinical phenotypes of patients with hereditary
disorders. More than 4,000 known genetic disorders are estimated to
affect roughly 1 in 10 individuals.
Click here for the full press release
https://corporate.qiagen.com/newsroom/press-releases/2017/2017-10-09-Centogene?sc_lang=en
Contacts:
QIAGEN
Public Relations
Dr. Thomas Theuringer
e-mail: pr@QIAGEN.com
+49-2103-29-11826
Investor Relations
John Gilardi
e-mail: ir@QIAGEN.com
+49-2103-29-11711
CENTOGENE
CEO´s office
Doreen Niemann
e-mail: press@centogene.com
+49-381-203-652-181
SOURCE Qiagen N.V.
Copyright 2017 PR Newswire
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024